Skip to main content
. Author manuscript; available in PMC: 2022 Aug 4.
Published in final edited form as: Eur J Cancer. 2021 Sep 25;157:391–402. doi: 10.1016/j.ejca.2021.08.013

Fig. 1.

Fig. 1.

Subsequent response for patients with SD, PR or CR at week 12 in the week 12 analysis population. Response was assessed by independent central review in KEYNOTE-001 and in KEYNOTE-006. CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease.